Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Common Equity (2016 - 2025)

Gsk has reported Common Equity over the past 11 years, most recently at $21.8 billion for Q4 2025.

  • Quarterly results put Common Equity at $21.8 billion for Q4 2025, up 24.15% from a year ago — trailing twelve months through Dec 2025 was $21.8 billion (up 24.15% YoY), and the annual figure for FY2025 was $21.8 billion, up 24.15%.
  • Common Equity for Q4 2025 was $21.8 billion at Gsk, up from $17.5 billion in the prior quarter.
  • Over the last five years, Common Equity for GLAXF hit a ceiling of $21.8 billion in Q4 2025 and a floor of $12.4 billion in Q4 2022.
  • Median Common Equity over the past 5 years was $17.5 billion (2024), compared with a mean of $17.7 billion.
  • Biggest five-year swings in Common Equity: tumbled 38.75% in 2022 and later soared 33.26% in 2023.
  • Gsk's Common Equity stood at $20.3 billion in 2021, then plummeted by 38.75% to $12.4 billion in 2022, then soared by 33.26% to $16.6 billion in 2023, then rose by 5.92% to $17.5 billion in 2024, then rose by 24.15% to $21.8 billion in 2025.
  • The last three reported values for Common Equity were $21.8 billion (Q4 2025), $17.5 billion (Q4 2024), and $16.6 billion (Q4 2023) per Business Quant data.